Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) EBIT (2019 - 2025)

Korro Bio's EBIT history spans 7 years, with the latest figure at $47.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 8.53% year-over-year to $47.0 million, compared with a TTM value of -$24.5 million through Dec 2025, down 39.76%, and an annual FY2025 reading of -$24.5 million, down 39.76% over the prior year.
  • EBIT for Q4 2025 was $47.0 million at Korro Bio, up from -$19.2 million in the prior quarter.
  • The five-year high for EBIT was $51.3 million in Q4 2024, with the low at -$27.2 million in Q2 2025.
  • Average EBIT over 5 years is -$13.5 million, with a median of -$20.8 million recorded in 2022.
  • Year-over-year, EBIT plummeted 563.03% in 2023 and then skyrocketed 290.93% in 2024.
  • Tracing KRRO's EBIT over 5 years: stood at -$21.4 million in 2021, then skyrocketed by 127.19% to $5.8 million in 2022, then plummeted by 563.03% to -$26.9 million in 2023, then skyrocketed by 290.93% to $51.3 million in 2024, then fell by 8.53% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's EBIT are $47.0 million (Q4 2025), -$19.2 million (Q3 2025), and -$27.2 million (Q2 2025).